Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T18:51:25.506Z Has data issue: false hasContentIssue false
  • English
  • Français

Relapse in schizophrenia: a review of the concept and its definitions1

Published online by Cambridge University Press:  09 July 2009

Ian R. H. Falloon ,
Grant N. Marshall ,
Jeffrey L. Boyd ,
Javad Razani  and
Cathy Wood-Siverio
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Psychological Medicine , Volume 13 , Issue 3 , August 1983 , pp. 469 - 477
Copyright
Copyright © Cambridge University Press 1983

References

Abuzzahab, F. S. & Zimmerman, R. L. (1980). Factors determining patient tenure on a 3-year double-blind investigation of pimozide versus fluphenazine HCI. Advances in Biochemical Psychopharmacology 24, 547–550.Google Scholar
Bleuler, E. (1911). Dementia Praecoxs: Or the Group of Schizophrenias (transl. Zinkin, J.). International Universities Press: New York.Google Scholar
Bleuler, M. (1974). The long-term course of the schizophrenic psychoses. Psychological Medicine 4, 244–254.CrossRefGoogle Scholar
Chapman, L. J. & Chapman, J. P. (1980). Scales for rating psychotic and psychotic-like experiences as continua. Schizophrenia Bulletin 6, 476–489.CrossRefGoogle ScholarPubMed
Chouinard, G., Annable, L. & Kropsky, M. (1978). A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Pharmacology 18, 148–154.CrossRefGoogle ScholarPubMed
Ciompi, L. (1980). Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin 61, 606–618.CrossRefGoogle Scholar
Claghorn, J. L., Johnstone, E. E. & Cook, T. H. (1974). Group therapy and maintenance treatment of schizophrenics. Archives of General Psychiatry 31, 361–365.CrossRefGoogle ScholarPubMed
Clark, M.L., Huber, W. K. & Hill, D. (1975). Pimozide in chronic schizophrenic outpatients. Diseases of the Nervous System 36, 137–141.Google ScholarPubMed
Crawford, R. & Forrest, A. (1974). Controlled trial of depot fluphenazine in outpatient schizophrenics. British Journal of Psychiatry 124, 385–391.CrossRefGoogle Scholar
Crow, T. J. (1980). Molecular pathology of schizophrenia: more than one disease process? British Medical Journal 280, 66–68.CrossRefGoogle ScholarPubMed
del Guidice, J., Clark, W. G. & Gocka, E. F. (1975). Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16, 32–36.CrossRefGoogle Scholar
Donlon, P. T. & Meyer, J. E. (1978). A twelve month comparison of penfluridol and trifluoperazine in chronic schizophrenic outpatients. Journal of Clinical Psychiatry 39, 582–587.Google ScholarPubMed
Falloon, I. R. H., Watt, D. C. & Shepherd, M. (1978). A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine 8, 59–70.Google Scholar
Gelder, M. G., Marks, I. M. & Wolff, H. H. (1967). Desensitization and psychotherapy in the treatment of phobic states: A controlled inquiry. British Journal of Psychiatry 113, 53–73.CrossRefGoogle Scholar
Herz, M. I. & Melville, C. (1980). Relapse in schizophrenia. American Journal of Psychiatry 137, 801–805.Google ScholarPubMed
Hirsch, S. R. (1982). Depression revealed in schizophrenia. British Journal of Psychiatry 140, 421–422.CrossRefGoogle ScholarPubMed
Hirsch, S. R., Gaind, R. & Rohde, P. D. (1973). Outpatient management of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. British Medical Journal i, 633–637.CrossRefGoogle Scholar
Hogarty, G. E., Goldberg, S. C. & NIMH Collaborative Study Group (1973). Drug and sociotherapy in the aftercare of schizophrenic patients: one-year relapse rates. Archives of General Psychiatry 28, 54–64.Google Scholar
Hogarty, G. E., Schooler, N. & Ulrich, R. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36, 1283–1294.CrossRefGoogle ScholarPubMed
Huber, G., Cross, G. & Schuttler, R. (1981). Longitudinal studies of schizophrenic patients. Schizophrenia Bulletin 6, 592–605.CrossRefGoogle Scholar
Kane, J. M., Rifkin, A. & Quitkin, F. (1979). Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Research 1, 341–348.CrossRefGoogle ScholarPubMed
Kraepelin, E. (1919). Dementia praecox and paraphrenia. In The Textbook of Psychiatry (transl. Barclay, R. M.). Robert E. Krieger: New York.Google Scholar
Krawiecka, M., Goldberg, D. & Vaughan, M. (1977). A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica 55, 299–308.Google Scholar
Leff, J. P. (1973). Influence of selection of patients on results of clinical trials. British Medical Journal iv, 156–158.CrossRefGoogle Scholar
Leff, J. P. & Wing, J. K. (1971). Trial of maintenance therapy in schizophrenia. British Medical Journal iii, 559–604.Google Scholar
Linn, M. W., Caffey, E. M. & Klett, J. (1979). Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. Archives of General Psychiatry 36, 1055–1066.CrossRefGoogle ScholarPubMed
McGlashan, T. H. & Carpenter, W. T. Jr (1976). Postpsychotic depression in schizophrenia. Archives of General Psychiatry 33, 231–239.Google Scholar
Meyer, A. (1922). Constructive formulation of schizophrenia. American Journal of Psychiatry 1, 355.CrossRefGoogle Scholar
O'Brien, C. P., Hamm, K. B. & Ray, B. A. (1972). Group vs. individual psychotherapy with schizophrenics. Archives of General Psychiatry 27, 474–478.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799–812.CrossRefGoogle Scholar
Quitkin, F., Rifkin, A. & Kane, J. (1978). Long-acting oral vs. injectable antipsychotic drugs in schizophrenics. Archives of General Psychiatry 35, 889–892.CrossRefGoogle ScholarPubMed
Rifkin, A., Quitkin, F. & Rabiner, C. J. (1977). Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics: I. Relapse rates after one year. Archives of General Psychiatry 34, 43–47.Google Scholar
Schooler, N. R., Levine, J. & Severe, J. B. (1980). Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Archives of General Psychiatry 37, 16–24.CrossRefGoogle ScholarPubMed
Sheldrick, C., Jablensky, A., Sartorius, N. & Shepherd, M. (1977). Schizophrenia succeeded by affective illness: catamnestic study and statistical inquiry. Psychological Medicine 7, 619–624.CrossRefGoogle Scholar
Sloane, R. B., Staples, F. R. & Cristol, A. H. (1975). Psychotherapy versus Behaviour Therapy. Harvard University Press: Cambridge, Mass.CrossRefGoogle Scholar
Valliant, G. E. (1964). Prospective prediction of schizophrenic remission. Archives of General Psychiatry 11, 509–518.CrossRefGoogle Scholar
Vaughn, C. E. & Leff, J. P. (1976). The influence of family and social factors on the course of psychiatric illness: a comparison of schizophrenic and depressed neurotic patients. British Journal of Psychiatry 129, 125–137.CrossRefGoogle ScholarPubMed
Wing, J. K. (1968). Social treatments of mental illness. In Studies of Psychiatry (ed. Shepherd, M. and Davies, D. L.), pp. 17–31. Oxford University Press: London.Google Scholar
World Health Organization (1975). International Pilot Study of Schizophrenia. WHO: Geneva.Google Scholar